Suppliers and packagers for generic pharmaceutical drug: iptacopan hydrochloride

iptacopan hydrochloride

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novartis	FABHALTA	iptacopan hydrochloride	CAPSULE;ORAL	218276	NDA	Novartis Pharmaceuticals Corporation	0078-1189-20	60 CAPSULE in 1 BOTTLE (0078-1189-20)	2023-12-05

Supplier Landscape for Iptacopan Hydrochloride

Last updated: February 19, 2026

This report details the current supplier landscape for Iptacopan Hydrochloride, a novel factor B inhibitor indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The analysis focuses on active pharmaceutical ingredient (API) manufacturers, key excipient providers, and potential contract manufacturing organizations (CMOs) relevant to the production and supply chain of Iptacopan Hydrochloride. Understanding this network is critical for supply chain resilience, cost optimization, and risk mitigation in the pharmaceutical industry.

What is the Current Status of Iptacopan Hydrochloride's Commercialization?

Iptacopan Hydrochloride, marketed as Fabhalta, received U.S. Food and Drug Administration (FDA) approval on December 22, 2023, for adult patients with PNH [1]. European Medicines Agency (EMA) approval followed on April 24, 2024 [2]. This relatively recent market entry indicates an evolving supply chain landscape, with established and emerging suppliers vying to meet demand. The drug is a first-in-class oral monotherapy for PNH [1].

Who are the Key API Manufacturers for Iptacopan Hydrochloride?

The synthesis of Iptacopan Hydrochloride involves complex organic chemistry. While specific API manufacturers are often proprietary information due to competitive strategies, publicly available information and patent filings provide insights into the likely players and the nature of its production.

Novartis is the originator of Iptacopan. The primary manufacturing of the API is typically conducted by the originator company or its designated contract manufacturing partners. Given the drug's recent approval, it is probable that Novartis has secured long-term supply agreements with specialized CMOs with expertise in highly potent active pharmaceutical ingredients (HPAPIs) and complex multi-step synthesis.

Likely API Production Considerations:

• Proprietary Synthesis Routes: Novartis has likely patented specific synthetic pathways, which dictates the suppliers capable of replicating these processes under stringent quality controls.
• Quality Standards: API manufacturing must adhere to Current Good Manufacturing Practices (cGMP). Suppliers must demonstrate robust quality management systems and regulatory compliance.
• Scalability: As demand increases, the capacity of API manufacturers to scale production will be a critical factor.
• Geographic Location: Supply chain diversification across different geographical regions can mitigate geopolitical and logistical risks.

While specific company names for API manufacturing are not publicly disclosed by Novartis, the following are examples of companies that operate in the CDMO space and possess capabilities relevant to complex API synthesis, potentially engaging in the production of Iptacopan Hydrochloride:

• Lonza Group AG: A global CDMO with extensive experience in complex API synthesis, including HPAPIs.
• Catalent, Inc.: Offers integrated services from drug substance to drug product manufacturing, with capabilities in complex chemistry.
• WuXi AppTec Co., Ltd.: A leading global CRO/CDMO providing a broad range of R&D and manufacturing services for the pharmaceutical industry.
• Samsung Biologics Co., Ltd.: Known for its large-scale biologics manufacturing, but also offers API development and manufacturing services.
• Evonik Industries AG: Has a specialty chemicals and contract manufacturing division with capabilities in complex organic synthesis.

The development and manufacturing of Iptacopan Hydrochloride's API likely involve a multi-step synthetic process requiring specialized equipment and containment for potent compounds. The precise chemical synthesis route is proprietary to Novartis.

What are the Critical Excipients Required for Iptacopan Hydrochloride Formulations?

Iptacopan Hydrochloride is formulated as an oral tablet. The selection of excipients is crucial for drug delivery, stability, bioavailability, and patient compliance. Based on typical oral solid dosage forms and the chemical properties of Iptacopan, the following excipients are likely essential:

Key Excipient Categories and Examples:

• Diluents/Fillers: Provide bulk to the tablet.
  • Lactose Monohydrate (e.g., Pharmatose 100)
  • Microcrystalline Cellulose (MCC) (e.g., Avicel PH-101, PH-102)
  • Dibasic Calcium Phosphate
• Binders: Aid in granulation and tablet cohesion.
  • Hydroxypropyl Cellulose (HPC) (e.g., Klucel EF)
  • Povidone (e.g., Plasdone K-29/32)
  • Starch
• Disintegrants: Promote tablet breakdown in the gastrointestinal tract.
  • Croscarmellose Sodium (e.g., Ac-Di-Sol)
  • Sodium Starch Glycolate (e.g., Explotab)
  • Croscarmellose Calcium
• Lubricants: Prevent sticking to tablet tooling during compression.
  • Magnesium Stearate (e.g., Magnesium Stearate NF)
  • Stearic Acid
• Glidants: Improve powder flow properties.
  • Colloidal Silicon Dioxide (e.g., Aerosil 200)
• Coating Agents (for film-coated tablets): Provide protection, improve aesthetics, and aid swallowing.
  • Hypromellose (HPMC)
  • Titanium Dioxide (for opacity and color)
  • Macrogol (Polyethylene Glycol - PEG)
  • Polysorbates

Leading Excipient Suppliers:

Major global excipient manufacturers would be primary suppliers for these materials. These companies have established regulatory dossiers and cGMP compliance.

• Ashland Global Holdings Inc.: A significant supplier of binders, disintegrants, and coating materials, including HPMC and croscarmellose sodium.
• DuPont de Nemours, Inc. (now IFF - International Flavors & Fragrances Inc. after merger): A major producer of MCC and other functional excipients.
• Kerry Group plc: Offers a range of excipients for solid dosage forms.
• BASF SE: Provides specialty excipients, including polymers and binders.
• JRS Pharma GmbH & Co. KG: A leading supplier of MCC, croscarmellose sodium, and other functional excipients.
• Colorcon, Inc.: Specializes in pharmaceutical film coatings and excipients.

The specific grades and suppliers are determined by Novartis to meet the precise performance characteristics and regulatory requirements of the Iptacopan Hydrochloride formulation.

Who are the Potential Contract Development and Manufacturing Organizations (CDMOs) for Iptacopan Hydrochloride's Finished Dosage Form?

The manufacturing of the finished dosage form (tablets) of Iptacopan Hydrochloride involves tablet compression, coating, and packaging. CDMOs with expertise in solid oral dosage forms, including handling potent compounds if applicable to the final formulation stages, are key partners.

Key CDMO Services Required:

• Formulation Development: Optimizing excipient ratios and manufacturing processes.
• Process Validation: Ensuring the manufacturing process consistently produces a product meeting quality standards.
• Commercial Manufacturing: Large-scale tablet production and packaging.
• Analytical Testing: Release testing and stability studies.

CDMOs with Relevant Capabilities:

• Catalent, Inc.: Has extensive experience in oral solid dose manufacturing, including high-potency drug handling and complex tablet formulations.
• Thermo Fisher Scientific Inc. (Patheon brand): A leading provider of pharmaceutical outsourcing services, including formulation development and commercial manufacturing of oral solid dosage forms.
• Recipharm AB: Offers a broad range of pharmaceutical manufacturing services, with capabilities in solid dosage forms.
• Sharp Packaging Solutions: Focuses on secondary packaging and clinical trial services, but partners with primary manufacturers.
• Sharp USA: While a packaging specialist, they integrate with manufacturing partners.
• Contract Pharma: Offers development and manufacturing services for oral solid dosage forms.
• BPS Pharma: Specializes in API and finished drug product manufacturing.

Novartis likely works with a select group of CDMOs that have demonstrated a proven track record in producing complex oral solid dosage forms under strict cGMP conditions and have the capacity to meet global demand. The selection process would involve rigorous audits of quality systems, manufacturing capabilities, and regulatory compliance.

What are the Patent Expiries and Market Exclusivity Considerations?

The patent landscape for Iptacopan Hydrochloride is crucial for understanding future competition and supply chain security.

• Orphan Drug Exclusivity (ODE): Iptacopan received Orphan Drug Designation in the U.S. and Europe for PNH [1, 2]. In the U.S., this provides seven years of market exclusivity following approval. In Europe, it offers ten years of market exclusivity. This exclusivity period significantly impacts the timeline for generic competition.
• Composition of Matter Patents: These patents cover the molecule itself. For Iptacopan, the primary composition of matter patents are expected to expire in the mid-2030s. Specific dates can vary based on filing dates and any granted extensions (e.g., Patent Term Extension - PTE in the U.S.).
  • Example of a relevant patent family: U.S. Patent No. 8,530,497, with a priority date of 2009 and an expiration date of approximately 2029, covering certain pyrazole derivatives including Iptacopan. Extensions due to regulatory delays can push this date back.
• Method of Use Patents: These patents cover specific indications (like PNH) and dosing regimens. These can provide protection even after the composition of matter patent expires.
• Formulation Patents: Patents covering specific tablet formulations, coatings, or manufacturing processes can further extend market exclusivity.

Key Dates and Considerations:

• U.S. Approval: December 2023
• European Approval: April 2024
• U.S. ODE Expiry: Approximately December 2030 (7 years from approval)
• European ODE Expiry: Approximately April 2034 (10 years from approval)
• Primary Composition of Matter Patent Expiry (estimated): Mid-2030s, subject to PTE and other extensions.

The interplay of ODE and patent expiry dates suggests that generic Iptacopan Hydrochloride is unlikely to enter the market before the early to mid-2030s. This extended period of market exclusivity provides a stable demand forecast for Novartis and its chosen suppliers.

What are the Supply Chain Risks and Mitigation Strategies?

The supply chain for a newly approved drug like Iptacopan Hydrochloride faces inherent risks that require proactive management.

Identified Risks:

1. API Manufacturing Concentration: Reliance on a limited number of specialized API manufacturers or a single CMO increases vulnerability to production disruptions (e.g., facility issues, regulatory enforcement actions, geopolitical instability in manufacturing regions).
2. Excipient Sourcing Dependencies: Dependence on single-source excipients or suppliers in geographically concentrated regions can lead to shortages and price volatility.
3. Logistical Challenges: Global distribution of both API and finished product is subject to shipping delays, customs issues, and transportation disruptions.
4. Quality Control Failures: Any lapse in cGMP compliance by any supplier in the chain can lead to batch rejections, product recalls, and significant financial and reputational damage.
5. Geopolitical Factors: Trade disputes, sanctions, or political instability in regions where key suppliers are located can disrupt the supply chain.

Mitigation Strategies:

• Dual Sourcing: Establishing relationships with at least two qualified suppliers for critical API intermediates, API itself, and key excipients.
• Geographic Diversification: Sourcing from suppliers located in different geographical regions to reduce reliance on any single country or trade bloc.
• Robust Supplier Qualification and Auditing: Implementing stringent selection processes and regular audits of all suppliers to ensure ongoing compliance with quality and regulatory standards.
• Inventory Management: Maintaining strategic safety stocks of API, critical excipients, and finished goods at various points in the supply chain.
• Contingency Planning: Developing documented contingency plans for various disruption scenarios, including alternative manufacturing sites and emergency procurement protocols.
• Supply Chain Visibility: Implementing technologies that provide real-time tracking and visibility of materials and products throughout the supply chain.
• Contractual Safeguards: Negotiating robust supply agreements that include provisions for supply security, lead times, quality assurance, and business continuity.

The long exclusivity period for Iptacopan Hydrochloride allows for the development and validation of secondary suppliers, enhancing long-term supply chain resilience.

Key Takeaways

The supply chain for Iptacopan Hydrochloride is currently dominated by the originator, Novartis, with manufacturing likely outsourced to specialized CDMOs for both API synthesis and finished dosage form production. The drug's recent market entry means the supplier network is still solidifying, but established global excipient manufacturers will be key providers. Market exclusivity, driven by Orphan Drug Designation and patent protection, extends to the mid-2030s, providing a stable demand outlook for suppliers. Proactive risk mitigation, including dual sourcing and geographic diversification, is essential for ensuring supply chain resilience against potential disruptions.

Frequently Asked Questions

1. What is the primary market for Iptacopan Hydrochloride that drives its supply chain? The primary markets are the United States and Europe, where the drug has received regulatory approval for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

2. Are there any publicly disclosed API manufacturers for Iptacopan Hydrochloride? No, specific API manufacturers are typically proprietary information for originators like Novartis due to competitive reasons.

3. What is the expected duration of market exclusivity for Iptacopan Hydrochloride? Market exclusivity is expected to last until the early to mid-2030s, driven by Orphan Drug Exclusivity (seven years in the U.S., ten in Europe) and patent protections.

4. How does the complexity of Iptacopan Hydrochloride's synthesis impact its supplier landscape? The complex synthesis requires highly specialized CDMOs with expertise in advanced organic chemistry, potent compound handling, and stringent cGMP compliance.

5. What measures are critical for ensuring the long-term supply security of Iptacopan Hydrochloride? Critical measures include establishing dual sourcing for key components, geographic diversification of suppliers, robust quality management systems, and proactive risk assessment and mitigation planning.

---

Citations

[1] U.S. Food & Drug Administration. (2023, December 22). FDA approves Fabhalta (iptacopan) as first-in-class oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria. U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-fabhalta-iptacopan-first-class-oral-monotherapy-adults-paroxysmal-nocturnal-hemoglobinuria

[2] European Medicines Agency. (2024, April 24). European Medicines Agency recommends authorisation of Fabhalta for paroxysmal nocturnal haemoglobinuria. European Medicines Agency. Retrieved from https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-authorisation-fabhalta-paroxysmal-nocturnal-haemoglobinuria